Business, energy, technology, markets and global industry news from Business News Today

oncology

PharmaDeviceNews oncology
Representative image showing blood cancer clinical research and treatment review, reflecting Incyte’s tafasitamab frontMIND trial update in high-risk diffuse large B-cell lymphoma.
Pharma & Biotech

Is Incyte’s tafasitamab regimen strong enough to challenge first-line DLBCL standards?

Find out how Incyte’s tafasitamab data could reshape first-line high-risk DLBCL treatment after frontMIND’s EHA 2026 readout.

Read More
Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.
Pharma & Biotech

Merck moves Welireg earlier as FDA clears Keytruda combinations in high-risk ccRCC

Find out how Merck’s Keytruda and Welireg approval could reshape adjuvant clear cell renal cell carcinoma treatment.

Read More
Representative image: Hematology researchers review blood analysis data as Incyte Corporation’s INCA033989 data highlight potential progress in CALR-mutated myelofibrosis and essential thrombocythemia treatment.
Pharma & Biotech

Why Incyte INCA033989 could reshape essential thrombocythemia and myelofibrosis care

Find out how Incyte INCA033989 data could reshape CALR-mutated myelofibrosis and essential thrombocythemia treatment.

Read More
Representative image of an oncology infusion setting as Genmab’s epcoritamab data raises hopes for new elderly DLBCL and diffuse large B-cell lymphoma treatment options.
Pharma & Biotech

Genmab pushes epcoritamab deeper into frontline lymphoma with elderly DLBCL data

Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.

Read More
Representative image: An oncologist discusses colon cancer treatment options with a patient, reflecting Genentech’s Tecentriq Priority Review and the growing role of immunotherapy in stage III dMMR/MSI-H colon cancer care.
Pharma & Biotech

Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment

Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.

Read More
Representative image: Clinicians review a chest CT scan as AI-assisted lung nodule risk assessment gains attention through Tanner Health’s Optellum rollout, highlighting the push to improve early lung cancer triage in regional care.
Medical Devices & Diagnostics

Why Optellum’s deployment at Tanner Health could matter for lung cancer risk stratification

Find out how Tanner Health’s Optellum rollout could reshape AI lung nodule triage and early lung cancer detection in regional care.

Read More
Representative image of oncology researchers reviewing molecular data in a biotechnology lab, reflecting Johnson & Johnson’s Firefly Bio deal and the race to advance degrader antibody conjugates for hard-to-treat solid tumors.
Pharma & Biotech

Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform

Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.

Read More
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Representative image of cervical cancer treatment planning as Zai Lab’s TIVDAK approval expands China’s options for recurrent or metastatic disease.
Pharma & Biotech

TIVDAK approval gives Zai Lab a sharper China oncology story, but execution risk remains

TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.

Read More
Representative image of an oncology consultation, illustrating how Roche and Genentech’s giredestrant FDA priority review could reshape endocrine therapy decisions in early-stage breast cancer.
Pharma & Biotech

Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment

Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.

Read More